Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Sarasin & Partners LLP

Sarasin & Partners LLP trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 488,325 shares of the medical research company's stock after selling 71,851 shares during the period. Thermo Fisher Scientific accounts for approximately 2.8% of Sarasin & Partners LLP's holdings, making the stock its 17th largest holding. Sarasin & Partners LLP owned approximately 0.13% of Thermo Fisher Scientific worth $302,063,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Signature Resources Capital Management LLC boosted its stake in Thermo Fisher Scientific by 318.2% in the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock worth $25,000 after buying an additional 35 shares during the last quarter. New Millennium Group LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $29,000. Stephens Consulting LLC lifted its stake in shares of Thermo Fisher Scientific by 116.0% in the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock valued at $30,000 after purchasing an additional 29 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $32,000. Finally, Bank & Trust Co acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $33,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded up $3.13 during trading on Friday, reaching $596.92. The stock had a trading volume of 2,105,529 shares, compared to its average volume of 1,470,010. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. The stock has a market cap of $227.85 billion, a PE ratio of 38.29, a P/E/G ratio of 3.84 and a beta of 0.77. The firm's 50 day moving average price is $608.10 and its two-hundred day moving average price is $583.17.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating analysts' consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The business had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. During the same period in the previous year, the business earned $5.15 EPS. The business's quarterly revenue was down 1.4% on a year-over-year basis. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In related news, VP Lisa P. Britt sold 3,624 shares of the business's stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the completion of the transaction, the vice president now owns 13,699 shares in the company, valued at $8,397,760.98. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, VP Lisa P. Britt sold 3,624 shares of the business's stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the completion of the transaction, the vice president now owns 13,699 shares in the company, valued at $8,397,760.98. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company's stock, valued at $76,420,473.36. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 23,084 shares of company stock worth $14,094,292 in the last 90 days. 0.34% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. lifted their price objective on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an "overweight" rating in a research note on Friday, September 20th. Stephens initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, October 1st. They set an "overweight" rating and a $680.00 price target on the stock. Raymond James boosted their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an "outperform" rating in a research report on Thursday, July 25th. Evercore ISI boosted their price target on Thermo Fisher Scientific from $605.00 to $630.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Finally, Stifel Nicolaus boosted their price target on Thermo Fisher Scientific from $615.00 to $680.00 and gave the stock a "buy" rating in a research report on Friday, September 20th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average target price of $653.72.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.